Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain
Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...
Barchart on MSN5h
What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?
Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...
Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses
Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...
Benefits Pro3d
Bristol-Myers Squibb’s $2.6B pension risk transfer lawsuit is ‘frivolous,’ say industry groups
The ERISA Industry Committee, along with two other industry groups, is seeking the dismissal of the drugmaker’s PRT lawsuit ...
Bristol-Myers Squibb's SWOT analysis: stock faces challenges amid growth prospects
Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...
MedCity News8d
Bristol Myers Squibb
The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 ...
Buy Rating for Bristol-Myers Squibb Driven by Cobenfy’s Strong Sales Momentum and Growth Potential
Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...
NBC New York16d
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...
Cautious Outlook on Bristol-Myers Squibb: Sell Rating Maintained Amid Revenue Declines and Financial Challenges
Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...
Yahoo Finance10d
Bristol-Myers Squibb Company (NYSE:BMY) is largely controlled by institutional shareholders who own 77% of the company
To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ownership structure of the business. And the group that holds the biggest ...
Deep Dive Into Bristol-Myers Squibb Stock: Analyst Perspectives (9 Ratings)
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...